title: Respiratory syncytial viral infection in an infant with unrepaired anomalous left coronary artery from the pulmonary artery.
abstract: Abnormal origin of the left coronary artery from the pulmonary artery (ALCAPA) is a rare coronary anomaly in children that requires necessary and urgent repair. We report a child who was hospitalized with respiratory failure due respiratory syncytial viral (RSV) infection and was subsequently diagnosed with ALCAPA. Aggressive treatment for RSV included synagis and nebulized ribavirin prior to surgical repair. After waiting 4 weeks for the RSV infection to resolve, she underwent successful left coronary artery reimplantation on hospital day 27 and has regained normal left ventricular size and function.
authors: Pediatrics, The University of Texas Southwestern Medical Center, Children's Medical Center of Dallas, Dallas, TX 75235, USA. Karen.McClard@childrens.com
authors: Karen
authors: K
authors: McClard
authors: Joseph
authors: J
authors: Forbess
authors: Daniel
authors: D
authors: Stromberg
authors: Tia
authors: T
authors: Tortoriello
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006328:Cardiac Catheterization; D003330:Coronary Vessel Anomalies / Q000150:complications* / Q000175:diagnosis / Q000601:surgery; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007223:Infant; D009330:Nebulizers and Vaporizers; D000069455:Palivizumab; D011651:Pulmonary Artery; D012092:Replantation; D012131:Respiratory Insufficiency / Q000821:virology; D018357:Respiratory Syncytial Virus Infections / Q000150:complications* / Q000188:drug therapy; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D018615:Ultrasonography, Doppler, Color
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D012254:Ribavirin; D000069455:Palivizumab